Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SCCHN

Bristol Myers Squibb logo

BMS closes on Celgene merger after rebel investors bow out

News on Revlimid patent also positive

Bristol Myers Squibb logo

BMS defends Celgene buyout ahead of shareholder vote

BMS battles for hearts and minds before shareholder vote

Bristol-Myers Squibb (BMS) building

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”

Bristol-Myers Squibb (BMS) building

Reluctant shareholders threaten $74bn BMS merger with Celgene

Shareholders claim merger undervalues BMS but analysts convinced the deal will close

Celgene building

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

R2 met its primary endpoint of PFS in trials

Bristol Myers Squibb logo

BMS isn’t phased by Opdivo’s slowing growth – for now

Lung cancer filing withdrawn after FDA reservations

- PMLiVE

Nektar confirms BMS deal for NKTR-214 is on track

Shares in Nektar rose 10% in the wake of the presentation at JPM healthcare conference

- PMLiVE

BMS and Celgene deal sparks debate on pharma profit motive, more M&A

Biopharma backlash at Warren tweet, but Celgene tactics in the spotlight

Celgene building

BMS and Celgene announce $74bn merger

Huge news for sector, with new fourth-placed company to be created

- PMLiVE

BMS to test Vedanta’s bacterial therapy with Opdivo

Will be trialled in those with advanced or metastatic cancers

- PMLiVE

NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer

But it is only available via the CDF for now

- PMLiVE

FDA green lights BMS’ multiple myeloma combo

Speedy approval follows a breakthrough designation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links